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Abstract
Introduction. Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) is a selective suppressor of the 
immune response that has been linked to the evasion of immune surveillance by cancer cells. However, the exact 
prognostic impact of RCAS1 on epithelial ovarian cancer (EOC) has not been fully elucidated. The main aim 
of our study was to evaluate the influence of RCAS1 immunoreactivity (RCAS1-Ir) in EOC cells and in tumor 
stroma cells on patient overall survival. We also focused on RCAS1-Ir and the structure of the tumor stroma. 
Material and methods. RCAS1-Ir was evaluated by means of immunohistochemistry in 67 patients with EOC. 
We distinguished cytoplasmic and membranous immunoreactivity patterns. 
Results. We found that high cytoplasmic RCAS1-Ir in cancer cells was associated with more than a two-time 
shortened period of overall survival. Membranous RCAS1-Ir in cancer cells, as well as in tumor stroma mac-
rophages and fibroblasts, did not correlate with patient survival. RCAS1-Ir in the cytoplasm of cancer cells was 
positively correlated with the degree of tumor stroma infiltration by fibroblasts and macrophages, but not with 
RCAS1-Ir in these cells. On the other hand, membranous RCAS1-Ir in cancer cells was positively correlated 
with RCAS1-Ir in fibroblasts and macrophages, but not with their quantity.
Conclusions. Due to their different impacts on patient prognosis and tumor stroma structure, it seems that cyto-
plasmic and membranous RCAS1-Ir in EOC cells may have different biological functions. (Folia Histochemica 
et Cytobiologica 2019, Vol. 57, No. 3, 116–126)
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Introduction
Epithelial ovarian cancer (EOC) is still the leading 
cause of death from gynecological malignancies in 
the Western world [1]. Patient prognosis depends 
on the stage of the disease, patient age at diagnosis, 
the histological type of the tumor, and the first-line 
chemotherapy [2]. Current data suggests that the 
residual disease after primary debulking surgery is 
the most important prognostic factor in EOC [3, 4]
the prognostic role of complete and so-called optimal 
and suboptimal debulking and its interaction with 
biological factors has not been not fully defined. 
Exploratory analysis was conducted of 3 prospective 
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randomized trials (AGO-OVAR 3, 5, and 7. However, 
patient prognosis may be influenced by the structure 
and function of the tumor stroma [5, 6]. Chen et al. 
showed that stroma-rich ovarian cancer patients had 
a worse prognosis and higher risk of relapse compared 
to patients who had tumors with poorly developed 
stroma [7]. 
In 1996, Sonoda et al. discovered receptor-binding 
cancer antigen expressed on SiSo cells (RCAS1) as 
a membrane protein on uterine cervix cancer cells [8, 9]. 
RCAS1 has strong immunosuppressive activity and 
is linked with the evasion of immune surveillance by 
cancer cells. RCAS1 is responsible for the inhibition 
of both cytotoxic lymphocytes and natural killer 
(NK) cell activity [10]. Furthermore, RCAS1 may 
induce Fas-independent apoptosis of both T-cells 
and NK cells infiltrating the tumor microenvironment 
[11]. RCAS1 staining was also found on numerous 
noncancerous cells infiltrating the tumor stroma, 
such as tumor-associated macrophages (TAMs) and 
cancer-associated fibroblast (CAFs) [12]. Therefore, 
RCAS1 expression on cancer stroma cells may be 
responsible for the immune evasion of cancer cells 
and the development of a more cancer-permissive 
microenvironment facilitating tumor growth [12, 13].
By stimulating the expression of vascular endothelial 
growth factor (VEGF), RCAS1 also indirectly stim-
ulates angiogenesis [14]. RCAS1 expression was also 
associated with the increased secretion of matrix met-
alloproteinase 1 (MMP-1) and laminin-5 in cervical 
cancer [15]. Additionally, in their study, Sonoda et al. 
found that RCAS1 expression was negatively corre-
lated with the number of vimentin-positive stromal 
cells in EOCs [16, 17]. Taken together, such evidence 
suggests that RCAS1 may participate in the rebuilding 
of the tumor stroma.
RCAS1 expression in cancer cells has been shown 
to be a negative prognostic factor in patients with 
numerous types of human neoplasms, including 
gynecological malignancies [9, 18–20]. However, the 
exact role of RCAS1 in the survival of EOC patients 
is not fully understood. Furthermore, although 
RCAS1 expression has been observed in tumor stro-
ma macrophages and fibroblasts, there is sparse data 
concerning its influence on patient overall survival. 
Therefore, the main aim of our study was to evaluate 
the impact of RCAS1 immunoreactivity in both can-
cer and tumor stroma cells on EOC patient survival. 
Secondly, our goal was to observe whether RCAS1 
immunoreactivity influenced select features of the 
tumor stroma, such as fibroblast, macrophage, and 
lymphocyte infiltration or tumor stroma cellularity. 
Material and methods
Characteristics of patients. The study group consisted of 
67 samples of primary EOCs collected from women treated 
in the Clinical Department of Gynecological Oncology of 
the Lukaszczyk Oncological Center, Bydgoszcz, Poland, 
from 2005 through 2010. The median patient age was 58 
years (range 38–86). The median age of pre- and postmen-
opausal women was 49 years (range 39–56) and 59 years 
(48–84), respectively. The samples were obtained during 
primary cytoreductive surgery, and all patients achieved 
optimal cytoreduction (residual tumors each measuring 1 cm 
or less in maximum diameter). The study group included 
52 high-grade serous adenocarcinomas, 4 clear cell adeno-
carcinomas, and 11 endometrioid adenocarcinomas. Twelve 
tumors were graded as G2, and 55 as G3 cancers. EOCs 
were classified according to the then-current International 
Federation of Gynecology and Obstetrics (FIGO) system. 
Patients were subdivided according to the FIGO stage of the 
disease as follows: 16 stage II patients, and 51 stage III pa-
tients. The median follow-up for our patients was 35 months 
(range 0–160 months). This study received the Jagiellonian 
University Ethical Committee approval (KBET/89/B/2005 
and DK/KB/CM/0031/447/2010) and all patients gave written 
informed consent).
Immunohistochemistry. Immunohistochemical (IHC) re-
actions were performed using anti-RCAS1 (human) mAb 
(dilution 1:1000) purchased from Medical & Biological 
Laboratories Co., Ltd., Nagoya, Japan, Code No.: D060-3. 
All IHC studies were performed on 4 μm-thick sections 
taken from cancerous tumors fixed in 4% buffered-formalin 
and embedded in paraffin blocks. The specimens for IHC 
staining were selected according to routine histopathological 
protocols. Thus, among multiple tumor sections evaluated in 
hematoxylin and eosin (H&E) staining we selected the most 
representative specimen with the highest tumor volume and 
without necrosis. Paraffin sections were placed on Knittel 
Glass adhesive slides and incubated for 2 h in a chamber 
thermostat at 60°C. Prior to the automatic performance of 
the study, tissue sections were subjected to the dewaxing pro-
cedure followed by the thermal epitope detection (HIER) in 
a PT Link device using EnVision™ FLEX Target Retrieval 
Solution, High pH (50x) (K8002) (Dako, Carpinteria, CA, 
USA). Finally, the preparations were dehydrated in a se-
ries of alcohols and enclosed in a medium (Consul Mount, 
Thermo Fisher Scientific Inc., Waltham, MA, USA). This 
method was performed at room temperature (RT). In each 
instance, a control preparation was added to a series of 
patient samples. According to the recommendation by the 
antibody manufacturer breast cancer sections were used 
as a positive control. The sections were viewed in Nikon 
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Eclipse 80i microscope (Nikon Instruments Europe BV, 
Badhoevedorp, The Netherlands).
Evaluation of RCAS1 immunoreactivity. The RCAS1 immu-
noreactivity (RCAS1-Ir) in cancer cell cytoplasm and cancer 
cell membranes was evaluated separately. The evaluation of 
RCAS1-Ir was based on the Immunoreactive Score (IRS) 
and included the simultaneous assessment of the number 
of RCAS1-positive cells and the intensity of the immuno-
reactivity. Staining intensity was evaluated as negative (0) 
or positive with a grade of 1+ (pale brown), 2+ (brown), 
or 3+ (dark brown). The percentage of stained cells was 
evaluated using the subjective method of the succeeding 
approximations as previously described [21]. The IRS with 
the simultaneous assessment of staining intensity and the 
percentage of positive cells was conducted as follows: If 
the intensity of RCAS1-Ir in the cancer cell cytoplasm was 
assessed as 3+ in 70% of cells, while 30% had RCAS1-Ir 
evaluated as 2+, we calculated the immunoreactivity score 
(IRS) according to the formula: [(3 × 70) + (2 × 30)]/100 
= 2.7, where one hundred refers to 100 analyzed cells. The 
combined result of the staining intensity and the percentage 
of positive cells equaled 2.7 (range 0 to 3.0). The cut-offs 
to separate “low” and “high” RCAS1-Ir, were determined 
following Receiver Operating Characteristic (ROC) curve 
analysis with the endpoint (death) as a classification vari-
able. Therefore, the cut-offs for cancer cell cytoplasm and 
membranous RCAS1-Ir were 1.125 and 0.5, respectively. 
The evaluation of stromal cellularity was done by count-
ing the number of tumor stroma cells in the microscopic 
High Power Field (HPF). The cellularity was assessed as low 
(1+), moderate (2+), or high (3+). Similarly, using HPF, we 
have evaluated the number of fibroblasts, macrophages, and 
the degree of lymphocyte infiltration. The tumor stroma cells 
were differentiated solely based on cell morphology. The pa-
rameters mentioned above were quantified as follows: absent 
(lack of examined cells), low number (1+), moderate number 
(2+), or high number (3+). The RCAS1-Ir in macrophages 
and fibroblasts was very homogenous; thus we used only 
staining intensity for the evaluation. Staining intensity was 
evaluated as negative (0) and positive staining was graded 
as 1+ (pale brown), 2+ (brown), or 3+ (dark brown). The 
number of cells (macrophages or fibroblasts) was evaluated 
separately from the RCAS1-Ir in these cells. Representative 
images of RCAS1 staining are presented in Figure 1.
Statistical analysis. The nonparametric Mann-Whitney 
test was used to compare RCAS1-Ir within the subgroups 
studied. Correlations were calculated using the nonpara-
metric Spearman’s rho test. RCAS1-Ir in macrophages and 
fibroblasts relative to the patient’s menopausal status was 
studied using the Fisher-exact test. Survival analyses were 
conducted using the Kaplan-Meier survival curves and the 
differences in patient survival were compared using log-rank 
test. Multivariate survival analysis was conducted using Cox 
proportional-hazards regression with the stepwise entering 
method. Statistical analysis was conducted using MedCalc 
11.4.2.0 (MedCalc Software, Seoul, Republic of Korea), 
and GraphPad InStat 3.06 (GraphPad Software Inc., San 
Diego, CA, USA).
Results
Immunoreactivity of RCAS1 in cancer cells  
and tumor stroma
We found significantly higher RCAS1-Ir in the cyto-
plasm of the EOC cells of premenopausal patients 
compared to postmenopausal patients (P = 0.01); 
however, there were no differences between pre- and 
postmenopausal patients with respect to membra-
nous RCAS1-Ir in cancer cells (P = 0.88) (Table 1). 
There were no differences in cytoplasmic RCAS1-
Ir in tumor stroma macrophages and fibroblasts 
corresponding to menopausal status. In the case of 
macrophages, among the premenopausal women, 8 
cases showed absent or low immunoreactivity while 
9 showed moderate or high RCAS1-Ir; the results for 
postmenopausal women were 29 and 24, respectively 
(P = 0.78). In relation to the cytoplasmic RCAS1-Ir 
in fibroblasts, the results were as follows: 15 (absent 
or low) and 2 (moderate or high) for premenopausal, 
and 41 (absent or low) and 12 (moderate or high) for 
postmenopausal, P = 0.49). 
The detailed results of RCAS1-Ir according to 
the cell types studied and the results of tumor stroma 
analyses are summarized in Table 1.
Immunoreactivity of RCAS1 and patients survival 
Patients with high RCAS1-Ir in the cytoplasm of can-
cer cells had significantly worse median OS compared 
to patients with low RCAS1-Ir in the cytoplasm of the 
tumors (OS 31 months, range 0–160 vs. 73 months, 
range 1–160, P = 0.04). By contrast, we found no 
differences in patient survival with respect to high and 
low membranous RCAS1-Ir in cancer cells within the 
analyzed tumors. We identified improved survival in 
patients with a low quantity of fibroblasts within tumor 
stroma compared to patients with a moderate or high 
quantity of fibroblasts (median OS 91 months, range 
6–160 vs. 32 months, range 0–160; P = 0.03). Patient 
survival was unaffected by RCAS1 cytoplasmic im-
munoreactivity in macrophages, RCAS1 cytoplasmic 
immunoreactivity in fibroblasts, stromal macrophage 
quantity, stromal cellularity, or the degree of lympho-
cytic infiltration. The survival curves are presented in 
Figure 2. In the multivariate survival analysis including 
cytoplasmic RCAS1-Ir, the stage of the disease, tumor 
grade and histopathological type of the tumor, only 
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Figure 1. Representative microphotographs of RCAS1 immunoreactivity evaluated as Immunoreactive Score (RCAS1-IRS) 
in cancer cells and tumor stroma cells in ovarian serous adenocarcinoma. A. Homogeneous cytoplasmic RCAS1 immuno-
reactivity (RCAS1-Ir) in cancer cells assessed as 1+; and no RCAS1-Ir in cancer cell membrane (0+). B. Moderate (2+) 
and homogeneous RCAS1-Ir in cancer cells; no RCAS1-Ir in cancer cell membrane (0+). Tumor stroma contained large 
number (3+) of cancer-associated fibroblasts (CAFs) and a low number (1+) of tumor-associated macrophages (TAMs). 
Low (1+) RCAS1-Ir in TAMs. High (3+) RCAS1-Ir in CAFs. C. Heterogeneous RCAS1-Ir in both cancer cell cytoplasm 
and cell membrane. RCAS1-Ir in cancer cell cytoplasm was assessed as high (3+) in 10% of the cancer cells, moderate (2+) 
in 80% of the cancer cells, and low (1+) in 10% of the cells. Thus, RCAS1-IRS in this case was equal to 2 since [(3 × 10) 
+ (2 × 80) + (1 × 10)]/100 = 2. RCAS1-Ir in cancer cell membrane was assessed as high (3+) in 25% of the cancer cells, 
moderate (2+) in 5% of the cells, low (1+) in 60% of the cells and no reactivity (0) was found in 10% of the cells. Thus, 
RCAS1-IRS in cancer cell membrane was equal to 1.45 since (3 × 25) + (2 × 5%) + (1 × 60) + (0 × 10)]/100 = 1.45. 
D. The RCAS1-IRS in cancer cell cytoplasm and cell membrane was 1.8 and 1.45, respectively. E. The quantities of both 
TAMs and CAFs in the tumor stroma were assessed as moderate (2+). Similarly, RCAS1-Ir in TAMs and CAFs was as-
sessed as high (3+). F. Tumor stroma presented with a low quantity (1+) of TAMs and a moderate (2+) quantity of CAFs. 
RCAS1-Ir in TAMs cytoplasm was assessed as low (1+), no RCAS1-Ir (0) in CAFs. G. Tumor stroma with a moderate (2+) 
quantity of TAMs and a low (1+) quantity of CAFs. RCAS1-Ir in TAMs cytoplasm was assessed as high (2+), RCAS1-Ir in 
CAFs cytoplasm was assessed as low (1+). H. Tumor stroma with a high (3+) quantity of TAMs and a moderate quantity of 
CAFs (2+). RCAS1-Ir in the macrophages was assessed as high (3+), and RCAS1-Ir in CAFs as low (1+). Magnifications: 
A, B, E, F ×200; C, D, G, H ×400. 
A B
C D
E F
G H
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cytoplasmic RCAS1-Ir remained independent predic-
tor of patients’ overall survival (P = 0.026).
Immunoreactivity of RCAS1 and tumor  
stroma characteristics 
Cytoplasmic RCAS1-Ir in cancer cells did not cor-
relate with membranous RCAS1-Ir in cancer cells 
(R = 0.09, P = 0.44). RCAS1-Ir in the cytoplasm of 
fibroblasts was positively correlated with fibroblast 
quantity (R = 0.56, P < 0.0001). Similarly, RCAS1-
-Ir in macrophages was positively correlated with 
macrophage quantity (R = 0.75, P < 0.0001). Stroma 
cellularity was positively correlated with fibroblast 
quantity (R = 0.27, P = 0.02). On the other hand, 
Table 1. RCAS1 immunoreactivity (RCAS1-Ir) and tumor stroma characteristics in ovarian epithelial cancer
Immunological score (IRS) (Median and range)
Cytoplasmic RCAS1-Ir in cancer cells of premenopausal patients 1.80 (1.025–2.90)
Cytoplasmic RCAS1-Ir in cancer cells of postmenopausal patients 1.60 (0.35–2.70)
Membranous RCAS1-Ir in cancer cells of premenopausal patients 0.00 (0.00–2.00)
Membranous RCAS1-Ir in cancer cells of postmenopausal patients 0.06 (0.00–2.1)
RCAS1-Ir in stromal macrophages Number (%)
Absent 10 (14%)
Low 27 (39%)
Moderate 22 (31%)
High 11 (16%)
RCAS1-Ir in stromal fibroblasts Number (%)
Absent 2 (3%)
Low 54 (77%)
Moderate 11 (16%)
High 3 (4%)
Stromal fibroblast quantity in HPF Number (%)
Absent 0 (0%)
Low 12 (18%)
Moderate 31 (47%)
High 23 (35%)
Stromal macrophage quantity in HPF Number (%)
Absent 10 (14%)
Low 21 (30%)
Moderate 26 (37%)
High 13 (19%)
Lymphocytic infiltration Number (%)
Absent 0 (0%)
Low 20 (29%)
Moderate 13 (19%)
High 36 (52%)
Stroma cellularity Number (%)
Low 1 (1%)
Moderate 46 (66%)
High 23 (33%)
Cytoplasmic RCAS1-Ir and membranous RCAS1-Ir are expressed as Immunoreactivity Score (IRS) that was based on the simultaneous assessment 
of the number of RCAS1-positive cells and the intensity of the immunoreactivity as described in Methods. Stromal fibroblasts and macrophages 
quantity refer to the number of fibroblasts and macrophages, respectively, identified in tumor stroma under microscopic High-Power-Fields (HPFs) 
as described in Methods.
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Figure 2. Survival analyses according to RCAS1 immunoreactivity (RACS1-Ir) expressed as Immunoreactive Score (RCAS1-IRS) 
and analyzed tumor stroma features in ovarian cancer. A. Group 1: low RCAS1-Ir (n = 12, median overall survival (mOS) 
73 months, range 1–160) vs. Group 2: High RCAS1-Ir (n = 55, mOS 31 mo, range 0–160), P = 0.04. B. Group 1: Low RCAS1-Ir 
(n = 22, mOS 38 mo, range 0–160) vs. Group 2: High RCAS1-Ir (n = 48, mOS 32 mo, range 0–160), P = 0.85. C. Group 
1: absent or low RCAS1-Ir (n = 31, mOS 31 mo, range 0–160 vs. Group 2: High and moderate RCAS1-Ir (n = 36, mOS 
38 mo, range 0–156), P = 0.44. D. Group 1: absent or low RCAS1-Ir (n = 35, mOS 34 mo, range 0–160) vs. Group 2: High 
and moderate RCAS1-Ir (n = 32, mOS 38 mo, range 0–160), P = 0.73). E. Group 1: low RCAS1-Ir (n = 12, mOS 91 mo, 
range 6–160) vs. Group 2: moderate and high RCAS1-Ir (n = 55, mOS 32 mo, range 0–160), P = 0.03. F. Group 1: absent 
or low RCAS1-Ir (n = 53, mOS 32 mo, range 0–160) vs. Group 2: moderate and high RCAS1-Ir (n = 14,mOS 38 mo, range 
0–160), P = 0.32). G. Group 1: absent or low RCAS1-Ir (n = 20, mOS 31 mo, range 0–160) vs. Group 2: moderate and high 
(n = 47, mOS 40 mo, range 0–160), P = 0.13. H. Group 1: low and moderate RCAS1-Ir (n = 44, mOS 32 mo, range 0–160) 
vs. Group 2: high RCAS1-Ir (n = 23, mOS 36 mo, range 5–160), P = 0.28). n, refers to the number of patients.
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there was no correlation between stroma cellularity 
and macrophage quantity (R = 0.22, P = 0.06) and 
the degree of lymphocyte infiltration (R = –0.01, 
P = 0.93).
We found significantly higher RCAS1-Ir in the 
cytoplasm of cancer cells in EOC patients with a large 
number of macrophages and fibroblasts within the 
tumor stroma (Fig. 3). Cytoplasmic RCAS1-Ir in can-
cer cells did not differ depending on the lymphocyte 
infiltration rate and stroma cellularity. Similarly, the 
RCAS1-Ir in cancer cell cytoplasm was not associated 
with RCAS1 cytoplasmic immunoreactivity in tumor 
stroma macrophages and fibroblasts (Fig. 3). 
Median membranous RCAS1-Ir in cancer cells was 
significantly higher in tumors with high and moderate 
RCAS1-Ir in stromal macrophages compared to tumors 
with absent or low membranous RCAS1-Ir in cancer 
cells (Fig. 3). A similar observation was noted in the 
case of RCAS1-Ir in tumor stroma fibroblasts. Mem-
branous RCAS1-Ir in tumor cells was not associated 
with the quantity of fibroblasts and macrophages within 
the tumor microenvironment. Moreover, membranous 
RCAS1-Ir in cancer cells did not differ according to lym-
phocyte infiltration and tumor stroma cellularity (Fig. 3).
Discussion
In this study, we observed the relationships between 
the patterns of RCAS1 immunoreactivities and the 
long-term outcomes of EOC patients. We found that 
high RCAS1-Ir in cancer cell cytoplasm resulted 
in more than two-times shortened overall survival 
of EOC patients. On the other hand, membranous 
RCAS1-Ir in cancer cells did not influence patient 
survival. Several papers have revealed cytoplasmic 
and membranous RCAS1-Ir in cancer cells [22–24]
which may contribute to the ability of tumor cells to 
evade host immune surveillance. In this study, we 
investigated RCAS1 expression in ovarian cancer and 
precancerous lesions by immunohistochemical means. 
We then analyzed the relationship between RCAS1 
expression and clinicopathological variables, and 
examined whether RCAS1 expression is associated 
with infiltration of tumor-infiltrating lymphocytes 
(TILs). However, to the best of our knowledge, our 
observation is the first to separate cytoplasmic and 
membranous staining showing the different impact 
of these staining patterns on patient survival. This 
data suggests that RCAS1 located in the cytoplasm 
of cancer cells plays a different role than the protein 
within the membrane or that it may represent a dif-
ferent subpopulation of cancer cells.
Tumor RCAS1 expression has already been 
studied as a prognostic factor in various neoplasms, 
including gynecological malignancies [15, 25, 26].
Three separate studies have investigated RCAS1-Ir 
in patients with EOCs, linking it with the prognosis 
for ovarian cancer patients [16, 23, 24]. RCAS1 ex-
pression is related to the expression of matrix met-
alloprotease 1 and laminin 5 and angiogenesis. We 
examined whether RCAS1 contributes to connective 
tissue remodeling in epithelial ovarian cancer. RCAS1 
expression was studied retrospectively via immuno-
histochemistry. Samples were obtained from resected 
tumor tissues from 65 patients with epithelial ovari-
an cancer. Statistical analysis was done to correlate 
RCAS1 expression and clinicopathologic variables. 
The associations between RCAS1 expression and 
the number of vimentin-positive cells or microvessel 
density were evaluated. Western blot analysis was 
also performed to verify the perturbation of vimentin 
expression in fibroblast L cells, following stimulation 
by soluble RCAS1. RCAS1 expression was detected 
in 72.3% (47/65 total cases). The first report was done 
by Akahira et al. [23]. The authors showed that the 
RCAS1-Ir is higher in more advanced stages of the 
disease. However, no significant relationship was de-
tected between RCAS1-Ir and patient OS. Although 
the authors detected cytoplasmic RCAS1-Ir, they did 
not distinguish it from membranous immunoreactivi-
ty. Additionally, Akahira et al. used a different method 
of assessment than we did; they merely divided the 
tumors into RCAS1-positive and RCAS1-negative 
groups according to subjective assessment [23]. We 
used a broader assessment involving both the evalu-
ation of the percentage of RCAS1-positive cells and 
the immunoreactivity intensity. Similarly, Ali-Fehmi 
et al. investigated the immunoreactivity of RCAS1 
and other antigens in EOC [24]. They previously 
identified 65 proteins as diagnostically useful TAAs 
by profiling the humoral immune responses in ovarian 
cancer (OVCA). The authors did not observe any 
influence of RCAS1 immunoreactivity on patient 
survival. Like Akahira et al. [23], the authors detect-
ed cytoplasmic RCAS1-Ir, but did not distinguish 
it from the RCAS1-Ir on the cell surface. Further-
more, Ali-Fehmi et al. also used a different method 
of assessment than we did; they regarded tumors as 
RCAS1-positive when immunoreactivity was found 
in more than 5% of the tumor cells [24]. In their 
study, Sonoda et al. found no significant relationship 
between RCAS1-Ir and overall survival; however, the 
difference was very close to the level of significance 
(P = 0.06) [16]. Similarly, the method of assessment 
was different from the one we used; the authors clas-
sified tumors with high RCAS1-Ir when more than 
25% of cells were RCAS1 positive [16]. Consequently, 
the discrepancy between our study and the studies 
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Figure 3. The relationships between Immunoreactivity Score of RCAS1 (RCAS1-IRS) in ovarian cancer cells and the analyzed 
tumor stroma features. A. For the patients with absent and low immunoreactivity the median RCAS1-IRS was 1.5 (range 
0.35–2.6) and for moderate and high immunoreactivity IRS was 1.8 (range 0.5–2.9). B. For the patients with absent and low 
immunoreactivity the median RCAS1-IRS was 0.00 (range 0.00–2.00) and for moderate and high immunoreactivity IRS was 
0.30 (0.00–2.10). C. For the patients with absent and low immunoreactivity the median RCAS1-IRS was 1.6 (range 0.35–2.9) 
and for moderate and high immunoreactivity IRS was 1.8 (0.5–2.7). D. For the patients with absent and low immunoreactivity 
the median RCAS1-IRS was 0.00 (range 0.00–1.9) and for moderate and high IRS was 0.6 (0.0–2.1). E. For the patients with 
absent and low quantity of macrophages within tumor stroma the median RCAS1-IRS was 1.5 (range 0.00–2.60) and for 
moderate and high IRS was 1.8 (0.50–2.90). F. For the patients with absent and low quantity of macrophages within tumor 
stroma the median RCAS1-IRS was 0.00 (range 0.00–2.00) and for moderate and high IRS was 0.25 (0.00–2.10). G. For 
the patients with low quantity of fibroblasts within tumor stroma the median RCAS1-IRS was 1.5 (range 0.35–2.70) and for 
moderate and high IRS was 1.95 (0.90–2.90). H. For the patients with low quantity of fibroblasts within tumor stroma the 
median RCAS1-IRS was 0.00 (range 0.00–2.10) and for moderate and high IRS was 0.20 (0.00–2.10). I. For the patients with 
absent and low tumor stroma lymphocytic infiltration the median RCAS1-IRS was 1.65 (range 0.50–2.70) and for moderate 
and high IRS was 1.725 (0.35–2.90). J. For the patients with absent and low tumor stroma lymphocytic infiltration the median 
RCAS1-IRS was 0.00 (range 0.00–2.10) and for moderate and high IRS was 0.23 (0.00–2.10). K. For the patients with low 
and moderate tumor stroma cellularity the median RCAS1-IRS was 1.65 (range 0.50–2.70) and for moderate and high IRS 
was 1.70 (0.35–2.90). L. For the patients with low and moderate tumor stroma cellularity the median RCAS1-IRS was 0.00 
(range 0.00–2.10) and for moderate and high IRS was 0.3 (0.00–2.10).
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mentioned above could be explained by the different 
methods of RCAS1-Ir assessment. We consider our 
method of assessment to be more accurate because 
it includes both the number of RCAS1-positive cells 
and the intensity of immunostaining. Additionally, 
we have distinguished cytoplasmic from membranous 
immunoreactivity, even though only cytoplasmic 
immunoreactivity had an impact on patient survival. 
RCAS1 expression was also observed on noncan-
cerous cells infiltrating the tumor microenvironment, 
such as macrophages and fibroblasts; however, the 
clinical significance of this observation is still unknown 
[12, 27, 28]. Due to its selective immunosuppressive 
activity, RCAS1 expression on tumor stroma cells 
could potentially be responsible for creating tu-
mor-pervasive stroma which could in turn result in 
a shortened patient survival period. However, this as-
sociation has not yet been proven. Jozwicki et al. have 
also showed that higher RCAS1-Ir in tumor stroma 
macrophages and fibroblasts was present in ovarian 
neoplasms with lymph node metastases [29]. Galazka 
et al. demonstrated that RCAS1 expression in mac-
rophages and fibroblasts within cervical cancer stroma 
did not influence the FIGO stage of the disease and 
lymph node metastases; it also was not related to the 
grade of the tumor [12]. In our study, we did not find 
that RCAS1-Ir in macrophages and fibroblasts had an 
impact on patient survival. However, because of the 
positive correlation between cancer cell membranous 
RCAS1-Ir and RCAS1 presence in macrophages and 
fibroblasts, an interaction based on RCAS1 activity 
between these cells could exist. Further studies in this 
field are therefore needed. 
We found significantly higher RCAS1 immunore-
activity in the cytoplasm of EOC cells of the patients 
who were premenopausal compared to those who 
were postmenopausal. Although the exact mecha-
nism of this association is not fully understood, we 
speculate that RCAS1 expression may be influenced 
by hormonal status. RCAS1 is identical with the 
estrogen-responsive protein EBAG9 (estrogen re-
ceptor-binding fragment-associated gene 9), which 
is an estrogen-responsive gene, and the regulation of 
transcription is mediated by estrogen receptors [30]
(1998. Moreover, in their study, Akahira et al. found 
a highly significant positive correlation between 
RCAS1-Ir and estrogen receptor alpha expression 
[23]. Thus, we speculate that RCAS1 expression is 
related to higher estrogen levels. 
Previous data has suggested that RCAS1 can 
participate in tumor stroma rebuilding through 
interaction with noncancerous stromal cells (CAFs 
and TAMs), induction of apoptosis of tumor- 
-infiltrating lymphocytes, and facilitating angiogenesis 
[12, 13, 26, 31]. We focused on stroma infiltration by 
macrophages, fibroblasts, and lymphocytes and eval-
uated tumor stroma cellularity as a whole. We found 
that RCAS1-Ir in the cytoplasm of cancer cells was pos-
itively correlated with the degree of tumor stroma in-
filtration by both fibroblasts and macrophages, but did 
not correlate with the RCAS1-Ir in these cells. On 
the other hand, RCAS1 membranous immunoreactiv-
ity in cancer cells positively correlated with RCAS1-Ir 
in fibroblasts and macrophages, but not with their 
quantity. Our results suggest that RCAS1 may par-
ticipate in tumor stroma remodeling through the 
modification of tumor stroma infiltration by immune 
cells and fibroblasts. Additionally, this data supports 
the possibility of a different biological role for cytoplas-
mic as opposed to membranous RCAS1 localization. 
The main weakness of this study was limited study 
group. However, we included only type-II tumors 
according to Shih and Kurman model [32]. Further-
more, all of our patients underwent optimal cytore-
duction defined as the largest residual tumor nodule 
measuring 1 cm or less. Thus, in respect of patient 
prognosis, our study group was highly homogene-
ous. The homogenous character of our study group 
is supported by the results of multivariate survival 
analysis, where known risk factors were not linked 
with patient prognosis.
In conclusion, our results suggest that the presence 
of RCAS1 in cytoplasm of epithelial ovarian cancer 
cells seems to have a different biological function 
from the RCAS1 present on the membrane, as only 
cytoplasmic RCAS1-Ir correlated with patient overall 
survival. Additionally, the exact role of RCAS1-posi-
tive fibroblasts and macrophages within EOC stroma 
needs further elucidation, even though the presence 
of these cells is not associated with patient survival. 
Furthermore, we suggest that RCAS1 may participate 
in the rebuilding of the tumor microenvironment by 
the influence on tumor stroma infiltration by mac-
rophages and fibroblasts.
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